Floatz logo

Indocyanine Green

Invasive Breast Cancer

Case Comprehensive Cancer CenterSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

58 Active assets in the Invasive Breast Cancer cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
University of California, San Francisco
Phase 4BBB
Letrozole
Emory University
Phase 4BBB
EXEMESTANE
University of California, San Francisco
Phase 4BBB
Arimidex
Jonsson Comprehensive Cancer Center
Phase 4BBB
TRASTUZUMAB
Massachusetts General Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Indocyanine Green is also rated in:

cervical cancerDormant
BB
Indicative ·
70 / 100
View asset →
endometrial carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
vulva cancerDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →